XH001 injection plus T-cells for advanced gastric cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new treatment combining an injection (XH001) with specially made immune cells (T-cells) that target your tumor's unique markers. It's for people with advanced stomach cancer who have not responded to standard therapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have advanced stomach cancer that has not responded to or you cannot tolerate standard treatments.
- You have at least one tumor that can be measured on a scan, and your overall tumor size meets specific limits.
- Your doctor expects you to live at least 12 weeks.
- Your organs and bone marrow are working well enough.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a special type of immune cell therapy for people with advanced gastric cancer. The treatment uses your own immune cells that are specially trained to find and attack cancer cells. It may help when standard treatments have stopped working.
This trial tests a two-part treatment: an injection called XH001 plus a custom vaccine that trains your immune cells to attack tumors. It's for people with advanced stomach or bowel cancer that hasn't responded to at least two prior treatments.
This trial tests a new type of cell therapy that uses your own immune cells, modified to target proteins found on some stomach cancer cells. It is for people with advanced stomach cancer that has not responded to standard treatments.
This early-stage trial tests a new injection called XH001 as an additional treatment after surgery for patients with high-risk cancers that have come back. The goal is to check if it's safe and whether it helps prevent the cancer from returning again.
This early-phase trial tests a new type of immune cell therapy (TCRx T cells) for advanced stomach cancer that has not responded to standard chemotherapy. The goal is to see if these specially engineered cells can help your body fight the cancer.
This trial studies a new treatment called XH001 combined with standard immunotherapy and chemotherapy for people whose pancreatic cancer has been surgically removed. The goal is to see if this combination helps prevent the cancer from coming back.
Hear when a new Advanced Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.